14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
UFPT vs NVCR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, UFP Technologies Inc (UFPT) is the stronger overall head-to-head candidate over NovoCure Limited (NVCR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). UFPT carries a Unified Composite Score of 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin), whereas NVCR carries 47.6/100 (HOLD) at $11.30 (N/M Forward P/E, -16.4% operating margin).
Composite vs. Pillar Nuance: While NVCR currently prints a higher short-term Unified Composite Score (47.6/100 HOLD vs. UFPT 42.6/100 HOLD), UFPT captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (15.4% vs. -16.4% operating margin) and revenue trajectory (+11.6% vs. +15.7% YoY).
Technical & Structure Timing Caution: UFPT is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8); meanwhile NVCR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UFPT vs NVCR. Trailing 12-month operating profitability (UFPT 15.4% vs NVCR -16.4%) and valuation multiples (UFPT 24.7x vs NVCR N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $1.4B market capitalization and -16.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ UFPT vs NVCR Key Questions & Quantitative Answers
As of Nov 16, 2026, UFP Technologies Inc (UFPT) is the stronger overall head-to-head candidate over NovoCure Limited (NVCR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). UFPT carries a Unified Composite Score of 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin), whereas NVCR carries 47.6/100 (HOLD) at $11.30 (N/M Forward P/E, -16.4% operating margin). Composite vs. Pillar Nuance: While NVCR currently prints a higher short-term Unified Composite Score (47.6/100 HOLD vs. UFPT 42.6/100 HOLD), UFPT captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (15.4% vs. -16.4% operating margin) and revenue trajectory (+11.6% vs. +15.7% YoY). Technical & Structure Timing Caution: UFPT is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8); meanwhile NVCR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NVCR leads the Growth & Scale pillar: UFPT posts +11.6% YoY revenue growth and +25.1% YoY earnings growth on $650M TTM revenue (28.9% gross margin, 15.4% operating margin), compared with NVCR at +15.7% YoY revenue growth and -6.0% YoY earnings growth on $725M TTM revenue (77.3% gross margin, -16.4% operating margin). On trailing 12-month operating scale, UFPT generates $650M in USD-normalized revenue versus $725M for NVCR. In operating R&D and SG&A reinvestment, UFPT deploys 13.5% of Rev ($88M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NVCR.
UFPT screens cheaper on headline valuation multiples. UFPT trades at 24.7x Forward P/E, 31.2x Trailing P/E, 3.80x PEG, and 3.6x EV/Revenue (18.5% EBITDA margin), whereas NVCR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.1x EV/Revenue (-3.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UFPT (17.2% ROE) versus NVCR (-35.2% ROE) capital efficiency.
In options market volatility and institutional positioning, UFPT carries 42.3% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.64β · 77% Vol realized risk). By comparison, NVCR carries 114.1% implied volatility (19th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.33β · 63% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.